Foreign exchangenegative · 4 filings
“The decrease was primarily driven by foreign exchange in the period due to fluctuations in the Canadian and U.S.”10-Q · May 11, 2026 ↗
AbCellera Biologics Inc.
ABCL
Market read
AbCellera Biologics Inc.'s current read is isolated; its market group is not confirming.
No new filing conclusion is available. 0 of 17 group members are active now; 0 filing-linked outsiders are moving with the group, and 0 of 5 directly disclosed connections are confirming.
Company+4.2% todayVolume comparison unavailable
Market group0 of 17 activeHealthcare & Credit Tech · unavailable
Disclosed network0 of 5 confirmingNo filing-linked name is confirming now
What would change this read
Watch this read- ABCL's market-adjusted activity becomes unusual and at least one connected name confirms.
Invalidation: The isolated read changes if ABCL's group or a disclosed connection begins moving with it.
Research brief
The story so far
No new filing conclusion is available. 0 of 17 group members are active now; 0 filing-linked outsiders are moving with the group, and 0 of 5 directly disclosed connections are confirming.
Evidence that supports
No thresholded supportive filing evidence is available yet.
Evidence that challenges
No thresholded adverse filing evidence is available yet.
What would clarify the read
- ABCL's market-adjusted activity becomes unusual and at least one connected name confirms.
Company research
Understand the business, not just the ticker
Business model and earnings drivers
Use the company’s filings to identify the few operating, demand, cost, capital and regulatory variables that determine its earnings power.
Key research questions
- Which operating variable is changing?
- Is that change durable, cyclical or one-off?
- What evidence would disprove the current interpretation?
Annual periods7
Price observations320
Usable filing statements75
Verified relationships7
Evidence supporting the case
- Latest annual revenue changed +160.6% year over year.
- Operating margin changed +802.7 percentage points in the latest annual period.
- Net margin changed +369.9 percentage points in the latest annual period.
Evidence challenging the case
- Foreign exchange has repeated adverse evidence across 4 filings.
- Product pipeline and R&D has repeated adverse evidence across 4 filings.
Questions before a position
- EV/sales is 989% above the available filing-peer median; determine whether growth and quality justify the difference.
Longer-term price context
Price as of Sep 11, 2026
10.906m+185.2%12m+153.4%24m—
Annual trajectory
Reported annual revenue and per-share history. This is accounting history, not a forecast.
PeriodRevenueYoYDiluted EPSShare change
2021-12-31$375.2M+60.9%$0.48+21.0%
2022-12-31$485.4M+29.4%$0.50-1.1%
2023-12-31$38.0M-92.2%$-0.51-8.2%
2024-12-31$28.8M-24.2%$-0.55+1.8%
2025-12-31$75.1M+160.6%$-0.49+1.5%
What management says matters
Persistent and emerging business drivers
Product pipeline and R&Dnegative · 4 filings
“The decrease of $29.1 million since December 31, 2025, was primarily from a combination of cash flow used in operations due to our continued research and development activity for internal programs in discovery, preclinical, and clinical development as well as…”10-Q · May 11, 2026 ↗
Supply chain and availabilitymixed · 4 filings
“Adjustments resulting from financial statement translations are included as a separate component of shareholders’ equity.”10-Q · May 11, 2026 ↗
Legal and regulatory exposurenegative · 2 filings
“This was partially offset by the first $18.0 million installment of a $36.0 million litigation settlement, with the remaining $18.0 million expected in the second quarter of 2026.”10-Q · May 11, 2026 ↗
Valuation discipline
Descriptive valuation snapshot
Price/sales 43.3× · EV/sales 41.6×. Comparisons use only industry-matched filing peers.
Scenario scaffold
Mechanical 2.0-year scenarios are available as editable assumptions, not consensus.
Price action
How the market is pricing the story
10.90+4.2% today
Jodie does not have enough daily observations to draw a useful short-term chart for this asset. The latest quoted price was checked 11 Sept, 15:55 GMT-4; this is a coverage limitation, not a flat-price conclusion.
Developments
No sourced recent-development timeline yet
Jodie has not returned a relevant primary source or news item for ABCL. This is an evidence-coverage gap, not a conclusion that nothing material happened.
Business and financial condition
Reported financial figures are not available yet
Jodie has not returned structured SEC XBRL fundamentals for this asset. This is a coverage limitation, not an assessment of the business or its financial health.
Filing analysis
No comparable filing assessment is available yet
Jodie has not yet found a suitable current-versus-prior filing comparison for ABCL. This does not mean the latest filing was neutral or immaterial.
Business ecosystem
The relationships behind ABCL
Customers, suppliers, partners and competitors named in company filings—not inferred from headlines.
Depends on
BRKRBruker CorporationpartnerMay 11, 2026 ▾
“For example, we were engaged in a lawsuit with Bruker Cellular Analysis (“Bruker”) based upon our allegations of its infringement of our intellectual property rights that we settled in December 2025.”
LINELineage, Inc.investeeMay 11, 2026 ▾
“Through our acquisition of Lineage, we obtained patents and patent applications directed toward immune-repertoire sequencing.”
Depended on by
RLYBRallybio CorporationpartnerAug 7, 2025 ▾
“This multi-year, multi-target collaboration will combine AbCellera Biologics Inc.'s ("AbCellera's") antibody discovery engine with our clinical and commercial expertise in rare diseases to identify optimal clinical candidates with a goal of delivering therapi…”
Filing peers
Companies whose filings use similar operating language.
Open the three relationships above to see Jodie’s filing proof. Pro unlocks 9 more links, every receipt, and alerts when connected names begin moving. Unlock the full network →
What is moving around it
Live connections
ABCL is currently a Follower in the organic co-movement group Healthcare & Credit Tech. This group is discovered from market behaviour rather than assigned from an industry taxonomy. 3 filing-linked names are in the relationship map; none is currently confirmed as moving with the group.
This group is retained as the last observed read for ABCL; it is not active in the latest market snapshot.
Context history
Theme membership history
No durable theme membership has been observed for this name yet.